The Food and Drug Administration said on Friday that it had identified
another product contaminated with Hepatitis A, which was the cause of a
recall of frozen organic berries earlier this month.
As a result, the Scenic Fruit Company of Gresham, Ore., has recalled
three different lots of its Woodstock Frozen Organic Pomegranate
Kernels, which were shipped from February through May to United Natural
Foods Inc. distribution centers in 12 states – California, Colorado,
Connecticut, Florida, Georgia, Indiana, Iowa, New Hampshire,
Pennsylvania, Rhode Island, Texas and Washington.
The F.D.A. said the centers might have distributed the pomegranate seeds to grocery stores in other states.
LAS VEGAS — After seven weeks of testimony, a jury in Las Vegas is
due to begin deliberating Friday whether a former endoscopy clinic owner
and his former employee are guilty of murder, patient neglect,
insurance fraud and other criminal charges in a 2007 hepatitis C
outbreak described as one of the largest ever in the U.S.
A prosecutor, David Staudaher, ended 11 hours of
closing arguments by both sides Thursday telling the jury of seven
women, five men and five alternates that former Dr. Dipak Desai and
nurse anesthetist Ronald Lakeman recklessly and negligently put patients
at risk with the reuse of syringes and vials of the general anesthetic
propofol during procedures at a Desai clinic.
“It all comes down to trust,” Staudaher said, accusing
the clinic owner and the employee of disregarding the risk to patients
in order to save money.
Liver transplant recipients with hepatitis C experienced moderate
early response rates but frequent side effects from triple therapy with
antivirals in a recent study.
Researchers evaluated 60 liver
transplant recipients with recurrent HCV genotype 1 and significant
fibrosis who underwent treatment with pegylated interferon alfa-2a and
ribavirin (PEG/RBV) and either telaprevir (TVR) (n=35) or boceprevir
(BOC) (n=25), with a minimum follow-up of 12 weeks (mean follow-up, 35
weeks). Most patients were successfully placed on immunosuppressive
therapy with cyclosporine before treatment initiation, including 33 TVR
patients and 23 BOC patients.
Tuesday June 25, 2013 (foodconsumer.org) — A new study in Clinical Gastroenterology and Hepatology suggests that patients with hepatitis C virus may be better off not eating foods with cholesterol, which is found in meat and dairy products.
The study led by Lei Yu and colleagues shows that hepatitis C patients who had high intake of cholesterol were more likely than those with a low intake to have clinical or histologic progression of the infection.
This is important: The flu vaccine is recommended for those with HBV and HCV—Alan Franciscus.
25, 2013 — New research out of St. Michael’s Hospital has found that
despite popular belief, the flu shot is effective in preventing the flu,
even if the virus going around does not match the vaccine.
quite common for people to say they are not going to get the flu shot
this year because they’ve heard it does not match the strain of flu
going around,” said Dr. Andrea Tricco, the lead author of the paper and a
scientist at the Li Ka Shing Knowledge Institute of St. Michael’s
Hospital. “However, we’ve found that individuals will be protected
regardless of whether the flu strain is a match or not.”
SAN DIEGO, June 25, 2013 — /PRNewswire/ — Aethlon Medical, Inc.
(OTCQB: AEMD), announced today that the United States Food and Drug
Administration (FDA) has approved an Investigational Device Exemption
(IDE) that allows the Company to initiate human feasibility studies of
the Aethlon Hemopurifier® in the United States. The Hemopurifier®
is a first-in-class medical device that targets the rapid elimination
of life-threatening infectious disease and cancer glycopathogens from
the feasibility study protocol, Aethlon will enroll ten end stage renal
disease (ESRD) patients who are infected with the Hepatitis C virus
(HCV) to demonstrate the safety of Hemopurifier therapy. Successful
completion of the feasibility study will set the stage for Aethlon to
conduct pivotal studies required for market clearance to treat HCV and
potentially other disease conditions.